XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity (Tables)
9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Equity
 
  
Common Stock
Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
Controlling
Interests
Total
($ and shares in millions)
Shares
Par Value
Shares
Cost
Balance at January 1, 2016
3,577

$
1,788

$
40,222

$
45,348

$
(4,148
)
796

$
(38,534
)
$
91

$
44,767

Net income attributable to Merck & Co., Inc.



4,515





4,515

Other comprehensive loss, net of taxes




(104
)



(104
)
Cash dividends declared on common stock



(3,835
)




(3,835
)
Treasury stock shares purchased





44

(2,418
)

(2,418
)
Share-based compensation plans and other


(325
)


(25
)
1,235


910

Changes in noncontrolling ownership interests







124

124

Net income attributable to noncontrolling interests







13

13

Distributions attributable to noncontrolling interests







(15
)
(15
)
Balance at September 30, 2016
3,577

$
1,788

$
39,897

$
46,028

$
(4,252
)
815

$
(39,717
)
$
213

$
43,957

Balance at January 1, 2017
3,577

$
1,788

$
39,939

$
44,133

$
(5,226
)
828

$
(40,546
)
$
220

$
40,308

Net income attributable to Merck & Co., Inc.



3,440





3,440

Other comprehensive income, net of taxes




281




281

Cash dividends declared on common stock



(3,872
)




(3,872
)
Treasury stock shares purchased





36

(2,312
)

(2,312
)
Share-based compensation plans and other


(116
)


(13
)
739


623

Acquisition of Vallée







25

25

Net income attributable to noncontrolling interests







16

16

Distributions attributable to noncontrolling interests







(10
)
(10
)
Balance at September 30, 2017
3,577

1,788

39,823

43,701

(4,945
)
851

(42,119
)
251

38,499